| Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2025 and business updates. “We are pleased that we have secured additional financing that is expected to extend our cash runway through the first quarter of 2026,” sai. |
businesswire.com |
2025-05-15 12:35:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics Announces Pricing of $16 Million Offering |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the pricing of an offering of 834,237 shares of its common stock at an offering price of $6.61 per share and pre-funded warrants to purchase 1,587,108 shares of its common stock at an offering price of $6.6. |
businesswire.com |
2025-05-15 12:30:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Atara's active Investigational New Drug (IND) applications for the EBVALLO™ (tabelecleucel) program. “We are very pleased to. |
businesswire.com |
2025-05-05 21:06:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade |
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-13 15:14:15 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates |
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $1.19 per share versus the Zacks Consensus Estimate of a loss of $3.82. This compares to loss of $14 per share a year ago. |
zacks.com |
2025-03-07 20:10:20 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2024, business updates, and key upcoming milestones for 2025. “We will further narrow our focus on the future financial value of EBVALLO for the benefit. |
businesswire.com |
2025-03-07 18:01:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into Atara Biotherapeutics, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-03-02 13:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-03-01 13:00:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into Atara Biotherapeutics, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-28 13:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-27 12:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-25 12:00:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into Atara Biotherapeutics, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-24 12:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-23 12:00:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into Atara Biotherapeutics, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-22 12:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-21 13:00:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-20 13:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-19 13:00:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-18 13:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-17 13:00:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-16 13:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-15 13:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA |
NEW YORK, NY / ACCESS Newswire / February 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc.("Atara" or the "Company") (NASDAQ:ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-15 12:00:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-14 13:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet |
The consensus price target hints at a 33% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-02-14 12:56:18 |
Czytaj oryginał (ang.) |
| Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws |
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK , Feb. 14, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) ("Atara" or the "Company"). The investigation concerns whether Atara Biotherapeutics, Inc. and certain of its officers and/or directors have engaged in securities fraud. |
prnewswire.com |
2025-02-14 10:11:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-13 13:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA |
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-11 18:43:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 11, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-11 13:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA. |
accessnewswire.com |
2025-02-11 09:00:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why |
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-01-02 15:10:49 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 3:50 p.m. EST. A li. |
businesswire.com |
2024-11-27 18:01:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 6:10 a.m. PST / 9:10 a.m. EST. A. |
businesswire.com |
2024-11-13 18:01:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates |
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $2.93 per share versus the Zacks Consensus Estimate of a loss of $3.77. This compares to loss of $16.50 per share a year ago. |
zacks.com |
2024-11-12 20:16:32 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2024, recent business highlights, and key upcoming milestones. “With the first patient now enrolled in our Phase 1 NHL trial of ATA3219, we have taken an important ste. |
businesswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know |
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-10-15 17:00:20 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,500 restricted stock units of Atara's common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara. |
businesswire.com |
2024-10-04 20:01:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates |
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $3.10 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to loss of $17 per share a year ago. |
zacks.com |
2024-08-12 23:10:32 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2024, recent business highlights, and key upcoming milestones for 2024. “Building on the recent BLA acceptance with Priority Review for tab-cel, we are making signifi. |
businesswire.com |
2024-08-12 21:00:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy |
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2024-07-15 17:01:04 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 2,200 restricted stock units of Atara's common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara. |
businesswire.com |
2024-07-05 20:01:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 6:45 a.m. PDT / 9:45 a.m. EDT. A live web. |
businesswire.com |
2024-07-03 23:57:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy |
Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications, with a world-first allogeneic CAR-T approval in Europe and nearing FDA approval. Assuming no regulatory delays ATRA is well-funded to deliver proof-of-concept clinical data for its CAR-T platform in both B-cell malignancies and lupus, with an estimated cash runway into 2027. Despite fierce competition, ATRA's differentiated CAR-T platform combines all the best attributes of the competition, thus having a best-in-class potential. |
seekingalpha.com |
2024-07-03 17:39:37 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics' Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that EbvalloTM (tabelecleucel or tab-cel®) has been awarded the prestigious 2024 Prix Galien International Award for “Best Product for Orphan/Rare Diseases.” The award was presented to Pierre Fabre Laborato. |
businesswire.com |
2024-06-21 20:01:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern T. |
businesswire.com |
2024-06-17 12:00:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 9,700 restricted stock units of Atara's common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara. |
businesswire.com |
2024-06-07 20:01:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate in a fireside chat at the Goldman Sac. |
businesswire.com |
2024-06-05 20:01:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data supporting the potential of ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy candidate for the treatment of B-cell driven autoimmune diseases. Findings demon. |
businesswire.com |
2024-05-29 20:01:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA |
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Atara has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric patie. |
businesswire.com |
2024-05-20 13:25:00 |
Czytaj oryginał (ang.) |
| Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates |
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.72 per share a year ago. |
zacks.com |
2024-05-09 22:16:08 |
Czytaj oryginał (ang.) |